Reasons to collaborate

  • All randomised clinical trials involved in this collaboration have a slight difference in design. Dose of aspirin,duration of treatment and inclusion criteria vary. These difference offers a unique opportunity to answer many intriguing questions in subgroups.
  • Studies are all in different stages of execution. Trials can mutually give and get advice in the different hurdles that have to be taken to start up such large trials.
  • The information gathered by all separate trials is also mutually harmonized and by combining the large amount of available data, this will create the opportunity to pool these data and perform subgroup analysis, for example specific mutation analysis. In this manner, trials do not have to be unnecessarily large and the moment that aspirin can become regular treatment for cancer will be more close.

G.J. Liefers - ASPIRIN Trial

“If aspirin can become regular treatment for cancer, this will have a large impact on global health”